Pfizer (NYSE:PFE) recently announced positive topline results from its Phase 3 BASIS study for HYMPAVZI™ and declared a third ...

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential ...

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment ...

Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have ...

Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and ...

This article conducts technical analysis and provides forecasts for top trending stocks like Plug Power (PLUG), Uber, and ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely reflecting existing concerns.

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers, had a meeting with the Trump administration to talk about reducing US ...

Regardless of which you choose, Pfizer's (NYSE: PFE) share price has declined during the period. Pfizer's dismal stock ...

Investors in Pfizer Inc (Symbol: PFE) saw new options become available today, for the July 25th expiration. ... The put contract at the $23.00 strike price has a current bid of 58 cents.